## min read

Mood Stabilizers for Depression and Anxiety: What You Need to Know

|

October 27, 2026

Summarize with AI

Mood Stabilizers for Depression and Anxiety: What You Need to Know

Maybe a psychiatrist mentioned a mood stabilizer and you're trying to understand what that means. Maybe you've read that they help with depression or anxiety and you're wondering whether that's true. Mood stabilizers are a real and important group of medications, but their main job is narrower than a lot of online articles suggest.

According to the NIMH, mood stabilizers are typically used to treat bipolar disorder and mood changes associated with other mental disorders. They are sometimes added to other medications for depression. For anxiety disorders, other medications are usually the first choice.

What are mood stabilizers?

Mood stabilizers are medications that reduce extreme shifts in mood, especially the highs of mania and the lows of bipolar depression, and help prevent new episodes. The main groups are:

  • Lithium, which is approved for the treatment of mania and bipolar disorder
  • Certain anticonvulsants, medications first developed for seizures, such as valproic acid (Depakote) and lamotrigine (Lamictal)
  • Some antipsychotics, which are also used in bipolar disorder, though they aren't always called mood stabilizers

How do mood stabilizers work?

Lithium and the anticonvulsants act on the brain in different ways, which is part of why one person responds to lithium and another to an anticonvulsant. The NIMH notes, for example, that some anticonvulsants work better than lithium for people with "mixed" symptoms of mania and depression or with rapid-cycling bipolar disorder.

What matters most for patients is the effect: fewer and less severe mood episodes over time, rather than an immediate change in how you feel.

What mood stabilizers are used for

Bipolar disorder

This is the main use. According to MedlinePlus, lithium is used to treat and prevent episodes of mania in people with bipolar disorder. The NIMH adds that some studies indicate lithium may reduce the risk of suicide among people taking it for long-term maintenance.

For people with bipolar depression, the NIMH notes that health care providers typically prescribe a mood stabilizer along with an antidepressant to reduce the risk of switching into mania. We cover the full picture in effective bipolar disorder treatment and on our bipolar disorder treatment page.

Depression

The NIMH notes that mood stabilizers are sometimes used to treat depression, usually along with an antidepressant, or to augment the effect of other medications. That's an add-on role for specific situations, not a standard first treatment for depression. If depression has been severe or hard to treat, see what severe depression feels like.

Anxiety

Mood stabilizers aren't a standard treatment for anxiety disorders. According to the NIMH, anxiety is usually treated with antidepressants such as SSRIs and SNRIs, which health care providers typically start with for panic disorder and social anxiety disorder. Other options include buspirone, short-term benzodiazepines, and beta-blockers for physical symptoms. When anxiety comes with bipolar disorder, treating the bipolar disorder often matters most, which is where mood stabilizers come in.

Other uses

The NIMH also lists schizoaffective disorder and impulse-control disorders among the conditions where mood stabilizers are sometimes used.

Common mood stabilizers and their side effects

Lithium

Lithium needs close monitoring. The NIMH notes that people taking it generally have regular blood tests to check lithium levels and kidney and thyroid function, and MedlinePlus lists side effects including increased thirst, weight change, dry mouth, and stomach upset. Keeping lab appointments is part of taking lithium safely.

Lamotrigine (Lamictal)

According to MedlinePlus, lamotrigine is used to lengthen the time between mood episodes in people with bipolar I disorder. It hasn't been shown to treat an episode that's already happening. Its most important warning is a risk of rashes, including serious rashes that may need hospital treatment, which is why it's started at a low dose and increased slowly. MedlinePlus also notes that lamotrigine can make hormonal birth control less effective.

Valproic acid (Depakote)

Valproic acid is used to treat mania in bipolar disorder, according to MedlinePlus. It carries a serious warning for pregnancy: it can cause birth defects affecting the brain and spinal cord and can affect a child's learning and development. MedlinePlus advises women of childbearing age to discuss other possible treatments with their doctor.

Antipsychotics

Several antipsychotics are used in bipolar disorder. Their side effects differ, and some can affect weight, blood sugar, and cholesterol, so physical health monitoring is part of treatment.

Mood stabilizers vs. antidepressants

  • Antidepressants treat depression and are also widely used for anxiety disorders. The NIMH notes they usually take 4 to 8 weeks to work.
  • Mood stabilizers are mainly used to prevent and treat the highs and lows of bipolar disorder.

The difference matters most when someone might have bipolar disorder. That's why a careful evaluation of mood history, including any past periods of unusually high energy, little need for sleep, or racing thoughts, is an important part of choosing treatment.

What to know before and during treatment

  • Finding the right medication can take time. The NIMH notes that it may take several tries to find the medication that works best with the fewest side effects.
  • Don't stop suddenly. Changes to mood stabilizers should be made with a health care provider, because stopping abruptly can bring symptoms back.
  • Monitoring is part of the treatment. Lithium and several anticonvulsants need regular blood tests.
  • Pregnancy planning matters. Some mood stabilizers carry significant pregnancy risks, so family planning belongs in the treatment conversation.
  • Supplements aren't substitutes. Herbal products and supplements can interact with psychiatric medications, and none has been shown to replace a mood stabilizer for bipolar disorder. MedlinePlus lists interactions and warnings for common herbs and supplements.

How we approach medication at Amae Health

Bipolar Disorder and Major Depressive Disorder are among the conditions our clinics specialize in. Our psychiatrists manage medication as part of one treatment plan, alongside therapists, primary care physicians, dietitians, and care coordinators, so lab monitoring, side effects, and physical health are tracked together. For people who need more than weekly care, we offer an Intensive Outpatient Program (IOP) and a Partial Hospitalization Program (PHP).

Frequently asked questions

Can mood stabilizers treat anxiety?

They aren't a standard treatment for anxiety disorders. The NIMH lists antidepressants such as SSRIs and SNRIs, buspirone, short-term benzodiazepines, and beta-blockers as the usual options. Mood stabilizers matter most when anxiety occurs alongside bipolar disorder.

Are mood stabilizers used for depression?

Sometimes. The NIMH notes they may be added to an antidepressant to boost its effect, and they're central to treating bipolar depression. They aren't a typical first treatment for depression on its own.

What is the most common mood stabilizer?

Lithium is approved for the treatment of mania and bipolar disorder, according to the NIMH. Lamotrigine and valproic acid are also widely used. Which one fits depends on the person's symptoms, history, and other health factors.

Do mood stabilizers change your personality?

They're meant to reduce extreme mood episodes, not change who you are. If a medication leaves you feeling flat or unlike yourself, that's important to raise with your prescriber, because dose adjustments or a different medication may help.

What happens if you stop taking a mood stabilizer suddenly?

Stopping abruptly can bring mood symptoms back. Any change should be planned with a health care provider.

Key takeaways

  • Mood stabilizers are mainly used to treat and prevent the highs and lows of bipolar disorder.
  • They're sometimes added to antidepressants for depression, but they aren't a standard treatment for anxiety disorders.
  • Lithium may reduce suicide risk with long-term use and needs regular blood tests. Lamotrigine carries a serious rash warning, and valproic acid carries serious pregnancy risks.
  • Medication works best with careful monitoring and as part of a broader treatment plan.

If you or someone you love is living with bipolar disorder or depression that hasn't responded to treatment, request an intake appointment. Our team will explain how an evaluation works and what the first visit involves.

Reccomended for you

# min read

Dual Diagnosis vs Co-Occurring Disorders: Understanding the Differences

By

Sonia Garcia

|

November 10, 2026

Maybe a doctor wrote "dual diagnosis" in a discharge summary, and a treatment program's website says "co-occurring disorders." You're left wondering whether your family member has one condition, two, or something different from what you thought. Here's the short answer to the dual diagnosis vs co-occurring disorders question: they describe the same situation. Both terms mean a person has a mental health condition and a substance use disorder at the same time. The difference is in the wording, not the illness.

Dual diagnosis vs co-occurring disorders: what each term means

Co-occurring disorders is the term SAMHSA, NIDA, and NIMH use today. The Substance Abuse and Mental Health Services Administration (SAMHSA) uses it to describe a person who has at least one mental disorder and at least one substance use disorder, with each diagnosable on its own rather than one simply being a symptom of the other.

Dual diagnosis is another name for the same thing. SAMHSA's treatment guidance uses "co-occurring disorders" as its main term, and you'll see both on websites and in paperwork.

So if two websites seem to disagree, they're probably using different words for one clinical picture. What matters for care is which specific conditions are present and how severe each one is.

How common co-occurring disorders are

More common than most families expect. The National Institute on Drug Abuse notes that people with substance use disorders often have co-occurring mental disorders, and the reverse is true too. As NIDA notes, people treated for one condition can be screened for the other.

Two conditions, one person. Not two separate problems.

Why the two conditions feed each other

The relationship runs in both directions, and the National Institute of Mental Health points to several ways they connect:

  1. Shared risk factors. Genetics, chronic stress, and trauma raise the risk of both mental disorders and substance use disorders.
  2. Using substances to cope. Someone with untreated anxiety may drink to get through the evening. It works briefly, then makes the underlying condition worse.
  3. Substance use changing the brain. Repeated use can alter brain systems in ways that raise the risk of developing other mental disorders.

Which came first? Often, nobody can say for sure, and treatment doesn't wait for the answer.

Why diagnosis is harder when both are present

Intoxication and withdrawal can look almost exactly like psychiatric symptoms. Alcohol withdrawal, for example, can produce anxiety that's hard to tell apart from an anxiety disorder.

This is why a careful evaluation looks at timing: did the symptoms exist before the substance use, or do they persist for about a month or more after it stops? SAMHSA's TIP 42, following DSM-5, uses this test to separate an independent mental disorder from a substance-induced one. A firm answer can take weeks or months of abstinence.

It's worth the wait, because the answer informs the treatment plan. Picture someone whose untreated bipolar disorder drives their drinking: treat only the alcohol use and relapse is likely. Or someone whose anxiety was withdrawal all along: they may not need long-term psychiatric medication at all.

What integrated treatment looks like

For years, people with co-occurring disorders were told to get sober first, then address their mental health, or the reverse. Two separate systems, two separate teams, and the person caught in between.

The current standard is integrated treatment, which NIMH describes as care that combines mental health and substance use treatment rather than splitting it across providers. In practice, that usually means:

  • One coordinated treatment plan that names every condition and how each one affects the others
  • Psychiatric care that accounts for substance use when choosing and monitoring medications
  • Therapy for both conditions together, using approaches such as cognitive behavioral therapy and motivational interviewing
  • The right level of care, which may mean a structured outpatient program several days a week rather than a single weekly appointment
  • Support for physical health, sleep, and daily routines, since both conditions take a toll on the body

Medication choices are individual and depend on the specific diagnoses, the substances involved, and the person's history. That decision belongs with a psychiatrist who knows the full picture.

How we treat co-occurring disorders at Amae Health

Co-occurring substance use disorder is one of the conditions our clinics specialize in, alongside the severe mental illness (SMI) diagnoses we treat every day: schizophrenia, bipolar disorder, major depressive disorder, and borderline personality disorder.

Our care model brings a multidisciplinary team under one roof. Psychiatrists manage medication and the overall treatment plan. Therapists provide individual and group therapy. Primary care physicians, dietitians, health coaches, peer mentors, and care coordinators work from the same plan, so nobody has to carry information between offices.

For people who need more structure than weekly visits, we offer a Partial Hospitalization Program (PHP) and an Intensive Outpatient Program (IOP). If you're unsure which fits, our guide to PHP vs. IOP explains the difference.

Frequently asked questions

Is dual diagnosis the same as co-occurring disorders?

Yes. Both terms describe a person who has a mental health condition and a substance use disorder at the same time. "Dual diagnosis" is another name for co-occurring disorders.

Which comes first, the mental illness or the substance use?

It varies. Sometimes a mental health condition comes first and substance use begins as a way to cope. Sometimes substance use comes first and contributes to a mental disorder. Shared risk factors like genetics and trauma can drive both. A good evaluation looks at timing, but treatment can start before the order is clear.

Can both conditions be treated at the same time?

Yes, and federal guidance recommends it. Integrated treatment addresses the mental health condition and the substance use disorder through one coordinated plan instead of sending a person to separate programs in sequence.

What are common examples of co-occurring disorders?

Depression, anxiety, and bipolar disorder are among the mental health conditions NIMH names as often occurring alongside a substance use disorder. Many people also have anxiety and depression together alongside a substance use disorder.

The takeaway

When it comes to dual diagnosis vs co-occurring disorders, the labels differ but the clinical reality is the same: two or more conditions that shape each other and need to be treated together. The term on the paperwork matters far less than whether the care plan addresses all of them at once.

If you or someone you love is living with a mental health condition and substance use, request an intake appointment and a member of our team will talk through what's happening and which level of care fits.

If you're in crisis, call or text 988 to reach the 988 Suicide & Crisis Lifeline.

# min read

Schizophrenia Treatment Options: Navigating the Path to Recovery

By

Sonia Garcia

|

May 15, 2026

A schizophrenia diagnosis arrives to a person in a small room, and rearranges things without asking — the way a conversation feels, the way a plan for next year suddenly needs rewriting, the way someone you love looks at you and you can't quite tell what they're thinking anymore. Most of what you'll read about schizophrenia treatment options is either clinical to the point of cold, or optimistic in a way that skips the hard parts. 

Schizophrenia is a chronic condition. In 2026, it is also named one of the most treatable severe mental illnesses in psychiatry. The medications have quietly changed over the last two years, with the care models changing even faster. And the question clinicians now ask (is this person living a life they recognize as their own?) is a better question than the one psychiatry asked a generation ago.

This is a guide to what schizophrenia treatment actually looks like now.

What "Treatment" Means for Schizophrenia in 2026

For most of psychiatry's history, treating schizophrenia meant turning down the volume on hallucinations and delusions and hoping everything else would hold. Consequently, it often didn't. The older medications were blunt instruments — they could quiet the psychosis while leaving a person sedated, emotionally flat, and unable to concentrate. A patient could be symptom-free on paper and still lose their apartment, their job, and their social world, not because the illness had won, but because the treatment had taken too much with it.

That old goal has been replaced.

The modern target is functional recovery: the ability to live a connected, productive life, be it work or school. Rebuilding the relationships that came apart during the acute phase. Living on your own terms. Functional recovery is not the same as symptom elimination. Some of the people who reach it still hear voices, and some of the people with zero symptoms can't hold a routine. What functional recovery actually requires, almost without exception, is a care plan that treats medication, therapy, physical health, and social support as one whole problem instead of four.

Pharmacological Breakthroughs: A New Era of Medication

Medication is the floor of schizophrenia treatment, not the ceiling. For about 40 years, that floor was built of one material: antipsychotics that bind dopamine D2 receptors and block the signal. That is still the starting point for most patients in 2026. What has quietly changed is the field, which now has options that were not there two years ago.

Second-Generation Antipsychotics: The Current Standard

Risperidone, olanzapine, aripiprazole, paliperidone, quetiapine. Those are the names that will likely appear first in any conversation with a psychiatrist. They're called "second-generation" or "atypical" antipsychotics because together, they work on dopamine and serotonin, producing a more favorable profile for negative symptoms and cognitive effects than the drugs that came before them.

They work. They also come at a cost.

The trade-off is metabolic. Weight gain. Elevated blood sugar. Shifts in lipid panels that, untracked, add up to real cardiovascular risk over time. A care team that prescribes these medications without monitoring the body is doing half the job. Metabolic monitoring is not optional.

The Non-Dopaminergic Revolution: Cobenfy and Muscarinic Agonists

In September 2024, something happened in schizophrenia pharmacology for the first time in about 35 years. The FDA approved xanomeline-trospium (Cobenfy, formerly known as KarXT), and the mechanism was not a variation on the dopamine theme. Cobenfy works on muscarinic receptors (specifically the M1 and M4 subtypes), meaning the biological pathway it acts on is different in kind, not just in detail (Yale Medicine).

Here is why that matters.

Roughly one-third of patients don't respond adequately to dopamine-based medications. The metabolic and movement-related side effects of the older drugs are also downstream of dopamine blockade. Cobenfy doesn't block dopamine, which is why early trials suggest it may avoid some of that side effect profile.

Long-term data is still accumulating. For now, the field has its first new mechanism in a generation.

Long-Acting Injectables: Reducing the Daily Burden

Long-acting injectable antipsychotics, or LAIs, deliver a single dose that lasts weeks or even months. For patients whose relapses have traced back to missed pills, that is a meaningful shift.

The evidence has caught up with the intuition. A 2022 network meta-analysis in World Psychiatry pooled 92 randomized trials and 22,645 participants and found that LAIs hold up against daily oral antipsychotics in preventing relapse (Ostuzzi et al., 2022). Real-world studies of US Medicare patients have shown LAIs are associated with lower rates of psychiatric hospitalization and treatment discontinuation.

LAIs are not right for every patient. Some people find meaning in the daily ritual of a pill. Some have had painful experiences with injections. The right answer comes out of a real conversation with a psychiatrist who has the patient's history in front of them.

Models of Care: Why the Environment Matters

The same medication can produce very different outcomes depending on how it is delivered. Two patients on the same dose of the same drug can end up in very different places a year later. The difference is usually the system around them.

Coordinated Specialty Care (CSC)

In 2026, coordinated Specialty Care is the standard for early psychosis.It is also one of the clearest examples in psychiatry of a care model producing better outcomes than a new drug would. The American Psychiatric Association formally endorsed it in its 2020 practice guideline (APA Practice Guideline for the Treatment of Patients With Schizophrenia), and it came out of the NIMH RAISE research initiative.

The model is a single team of clinicians working from one plan: medication management, individual therapy, supported employment and education, family education, and case management that actually happens, rather than getting sent to five different offices on five different days.

The data is strong. In the NIMH RAISE Early Treatment Program, patients who received CSC had hospitalization rates of 23% compared with 44% in usual community care (NIMH: Team-based Treatment is Better for First Episode Psychosis). They were also more likely to stay in school or employment and experienced greater improvement in symptoms, interpersonal relationships, and quality of life (Kane et al., American Journal of Psychiatry, 2016).

That is a halving of hospitalization risk, produced by a care model rather than a new molecule.

CSC was built for early psychosis. For patients further along in treatment, other models fit better.

Integrated Outpatient Care for Severe Mental Illness

For patients past the first-episode window, integrated outpatient care takes the same principle as CSC and adapts it for the long haul. The model brings psychiatrists, therapists, primary care physicians, dietitians, health coaches, peer mentors, and clinical care coordinators under one roof, working from a single shared plan.

The problem it solves is fragmentation. In the usual picture, a patient has a psychiatrist at one office, a therapist at another, a primary care provider at a third, and if case management exists at all, it runs on lost email attachments. Small things become crises. Crises become hospitalizations. Hospitalizations become the next relapse.

But it doesn't have to work that way.

This is the model our integrated outpatient clinics are built on. We see adults 18 and older. Our care team is designed so that mental health, physical health, and everyday function are handled in the same place, by people who talk to each other. The patient is not the one running the coordination.

Crisis Services and Long-Term Stability

Crisis services are not long-term care, and long-term care is not crisis services. Inpatient hospitalization exists to keep people safe when symptoms are acute. It is essential, and it saves lives. But it is not designed to produce long-term stability, and the handoff from inpatient to outpatient is the highest-risk period for readmission. That handoff is where integrated outpatient care earns its keep.

Evidence-Based Psychosocial Interventions

Medication does one job well. It quiets the biology. Everything else is outside what a pill can do: how a person thinks about what is happening to them, how they rebuild relationships that came apart during the acute phase, how they get back into work or school.

That is where psychosocial interventions come in.

Cognitive Behavioral Therapy for Psychosis (CBTp)

CBT for Psychosis, usually shortened to CBTp, is not standard CBT with a few tweaks. It is a specialized protocol built from the ground up for people who hear voices, hold persistent unusual beliefs, or are trying to function while symptoms are still present. The APA practice guideline gives CBTp a 1B rating, which translates roughly to "the evidence is strong and clinicians should offer this" (APA Practice Guideline, 2020).

What CBTp actually does in a session is teach specific skills. Reality testing. Cognitive distancing from distressing voices. Stress-reduction techniques for the moments when symptoms spike. Coping strategies for persistent delusions that have not responded fully to medication. The goal is not to eliminate the symptoms. It is to change the relationship a person has with them.

Social Skills and Vocational Training

Skills erode during acute episodes. A patient who was holding a job six months ago and had friends two years ago can come back from a hospitalization and find that the conversational rhythm, the workplace reflexes, and the social scaffolding are all gone. Not permanently. Just not where they left them.

Structured social skills training is what it sounds like: deliberate practice. Starting conversations. Reading a room at work. Managing conflict without escalation. Re-entering relationships that went quiet during the acute phase. Supported employment programs pair these skills with real job coaching, and the evidence is that they help people get and keep work when traditional vocational rehabilitation has not.

Cognitive Remediation

Hallucinations and mood can stabilize while the harder, quieter symptoms persist: forgetting appointments, losing the thread of a conversation, struggling to plan a week. These are the symptoms that sit between "stable" and "back to a life I recognize." For many patients, they are what actually prevents the return to work or school.

Cognitive remediation is structured training for those skills. Memory exercises. Attention work. Executive function practice. The programs are not new, but they are one of the most underprescribed interventions in this space. They will not cure cognitive symptoms, but they can meaningfully improve day-to-day function.

The Role of Family and Community Support

No one recovers from schizophrenia alone. That is not a sentimental claim, but a finding that has been reproduced in study after study over several decades.

Family psychoeducation is one of the most consistently supported non-medication interventions in the books. The idea is simple: when the people a patient lives with understand what schizophrenia is, what the medications do, and how to communicate in hard moments, relapse rates drop. A concept in the research called "expressed emotion" describes a household climate marked by high levels of criticism, hostility, or emotional over-involvement. When that climate softens, relapse rates soften with it. Nothing about this says families cause schizophrenia. They don't. But the environment in which treatment either catches or slips is incredibly important.

Community reintegration carries the same weight. A stable apartment. A part-time job, even a small one. Peer support groups. A faith community if that fits. Friendships that survive the acute phase. These are not "lifestyle" factors that sit outside treatment. They are the treatment. A patient with housing and a routine has a very different clinical trajectory from the same patient without them.

How to Choose Among Schizophrenia Treatment Options

The question families ask us is almost never "should we get treatment." It is "how do we pick the right place." A few things matter more than the rest in that decision.

Start with the intake. A good assessment is not a form that takes 20 minutes to fill out. It is a conversation that covers psychiatric history, medication history and response, current symptoms, physical health, substance use, the home situation, and what the patient actually wants out of treatment. If the intake is structured as a checklist, the treatment plan will be too.

Ask how the team communicates. Is there a dedicated case manager? Does the psychiatrist read the therapist's notes? Is metabolic monitoring built into the schedule? Is family involvement standard? Are outcomes tracked? These are the questions we built our care model to answer, and a clinic that stumbles on them is worth a second look.

Insist on shared decision-making. A patient is a participant in their treatment, not a recipient of it. A good clinician lays out the trade-offs of each medication in plain language, listens to what the patient wants, and makes decisions alongside them. A clinician who rushes that or waves it off is telling you something.

Frequently Asked Questions

Q: Can schizophrenia be cured?

Not cured in the traditional sense. Schizophrenia is managed, which is a word that sounds smaller than it is. "Managed" in 2026 can mean living for decades with minimal disruption, working, keeping relationships, and needing medical care the way a person with diabetes does. Functional recovery is achievable for a meaningful number of patients, though not all.

Q: What happens if I stop taking my medication?

The risk of relapse rises sharply. What makes stopping tricky is the delay. Many people who discontinue antipsychotic medication feel fine for weeks, sometimes months, before symptoms return. That gap is long enough to conclude the medication wasn't necessary, and then to be caught off guard when symptoms do come back. Talk to your prescriber before making any changes.

Q: Are there natural treatments for schizophrenia?

Sleep, exercise, nutrition, and stress management support mental health and matter for anyone living with schizophrenia. They are not a substitute for medical treatment. If something is marketed as a "natural cure" for schizophrenia, that is a reason to stop reading. Supplements, herbs, and alternative therapies have not been shown to treat the underlying biology of the condition. Some interact with prescribed medications in ways that can be dangerous.

Q: How do I help a loved one who refuses treatment?

This is the question we hear most from families, and it is the hardest one. A few things help:

  • Anosognosia, a lack of awareness of one's illness, is itself a symptom of schizophrenia. It is not denial. Understanding the difference can change how you approach the conversation.
  • The LEAP method (Listen, Empathize, Agree, Partner), developed by Dr. Xavier Amador, was built for exactly these situations.
  • NAMI's Family-to-Family programs teach communication skills and connect families with others walking the same path.
  • In an acute safety crisis, call 988, the Suicide and Crisis Lifeline, or your local mobile crisis team.

Moving Toward Functional Recovery

A schizophrenia diagnosis is a serious event. It is not a verdict.

The range of schizophrenia treatment options has meaningfully widened since 2024. New medications. New evidence about old medications. Care models with strong outcomes data. Psychosocial interventions that help with the parts of recovery medication cannot touch. The clinical goal has moved from quieting the biology to helping a person live a life they recognize as their own.

What most patients and families need is not a single treatment.

They need a team that treats the whole picture, which means symptoms, physical health, relationships, work, and function, as one problem instead of four.

If you or someone you love is living with schizophrenia, schizoaffective disorder, or a related condition, Amae Health is here to talk. Our care teams include psychiatrists, therapists, primary care providers, dietitians, health coaches, peer mentors, and clinical care coordinators, all working from one shared plan. We see adults 18 and older at our clinics in Los Angeles, Los Altos, San Mateo, Raleigh, New York, and Brooklyn. To start the conversation, request an intake appointment.

‍

Citations

  1. 3 Things to Know About Cobenfy, Yale Medicine. Tier 4 (major academic medical center).
  2. Ostuzzi et al., "Oral and long-acting antipsychotics for relapse prevention in schizophrenia-spectrum disorders: a network meta-analysis of 92 randomized trials including 22,645 participants," World Psychiatry, 2022. Tier 1 (peer-reviewed).
  3. Kane et al., "Comprehensive Versus Usual Community Care for First-Episode Psychosis: 2-Year Outcomes From the NIMH RAISE Early Treatment Program," American Journal of Psychiatry, 2016. Tier 1 (peer-reviewed).
  4. NIMH: Team-based Treatment is Better for First Episode Psychosis. Tier 2 (government).

The American Psychiatric Association Practice Guideline for the Treatment of Patients With Schizophrenia, 2020. Tier 3 (professional association).

# min read

Does TMS Work for Bipolar Depression?

By

Sonia Garcia

|

November 20, 2026

In a study that followed people with bipolar I disorder for an average of 12.8 years, depressive symptoms were present in about 32% of weeks, compared with 9% for manic or hypomanic symptoms. In bipolar I disorder, depression is the part people live with most, which is why so many ask: does TMS work for bipolar depression?

The research is encouraging. A 2025 meta-analysis of 56 studies and 1,709 patients found response and remission rates on par with those for TMS in major depression. But TMS is not FDA-cleared for bipolar depression. It holds a breakthrough device designation, which is a different thing, and using it for bipolar depression is off-label.

How TMS Works for Bipolar Depression

The device and the basic method are the same ones used for major depression. A coil held against the scalp sends focused magnetic pulses into the prefrontal cortex, a brain region involved in regulating mood. No anesthesia is needed, and you stay awake throughout.

Side effects are usually mild. NIMH lists discomfort at the stimulation site, tingling or contraction of scalp, jaw, or face muscles during the pulses, mild headaches, and brief lightheadedness or dizziness. The rare serious risk is a seizure, which is why screening asks about seizure history before treatment starts.

What's different is what it's being used for. TMS for bipolar disorder treats one phase of the illness, the depressive episode, not the illness as a whole. It doesn't prevent future manic or depressive episodes. That remains the work of mood stabilization and ongoing care.

Protocols vary across the research. In the 2025 meta-analysis, the most common approach was high-frequency stimulation over the left dorsolateral prefrontal cortex, used in 24 studies. Low-frequency stimulation on the right side came next, in 10 studies, followed by a faster pattern called intermittent theta burst stimulation, in eight. The two most-studied approaches were each significantly associated with antidepressant effects. Left-sided theta burst stimulation and a right-then-left sequence also showed significant effects, with fewer studies behind them.

Is TMS FDA-Approved for Bipolar Depression?

No. The National Institute of Mental Health's overview of brain stimulation therapies lists rTMS as FDA-cleared for treatment-resistant depression, OCD, migraines, anxiety with depression, and smoking dependence. Bipolar depression is not on that list.

In 2020, the FDA granted rTMS a breakthrough device designation for bipolar depression. NIMH describes that designation as one given to devices with preliminary evidence of clinical effectiveness compared with available treatments. The FDA says its Breakthrough Devices Program is meant to speed up development and review of certain devices; designation is not authorization to market.

It isn't clearance.

Until a device is cleared for bipolar depression, using TMS for it is off-label. A psychiatrist can offer it based on clinical judgment, but that use hasn't been through the FDA review that the major depression indication has.

What the Research Shows About TMS for Bipolar Depression

The most comprehensive evidence comes from the 2025 systematic review and meta-analysis in Biological Psychiatry: Global Open Science. It pooled 56 studies covering 1,709 people with bipolar depression: 31 randomized controlled trials, 17 open-label trials, and eight retrospective studies.

Across all of those studies, about 47% of people responded to TMS and about 28% reached remission. The authors described those rates as on par with rates for unipolar depression, the standard use of TMS.

The sham-controlled trials carry the most weight, because they separate the treatment's effect from the effect of expectation. In those trials, active TMS roughly doubled the odds of both response and remission compared with sham stimulation. That works out to one additional responder for every eight people treated, and one additional remission for every nine.

The evidence has real limits. Many of the studies were small, protocols varied widely, and results were not broken out by bipolar I versus bipolar II. A 2026 meta-analysis limited to randomized trials found a smaller effect, with most individual trials not reaching significance on their own. Real-world data suggest the benefit carries over into everyday practice, though non-randomized estimates are more prone to bias, and reports conflict on whether TMS works better or worse in bipolar depression than in major depression. For a meaningful share of people, TMS does help bipolar depression. For any one person, it's a possibility to evaluate with a psychiatrist, not a promise.

Risk of Triggering Mania or Hypomania

Can TMS cause mania? For anyone with bipolar disorder, the risk of switching into mania or hypomania matters as much as whether a treatment works.

In the sham-controlled trials pooled in the 2025 meta-analysis, switches were uncommon in both groups: nine among people receiving active TMS and four among those receiving sham. The difference was not statistically significant (odds ratio 1.3, with a 95% confidence interval of 0.7 to 2.4).

Two caveats keep that reassurance in proportion. Small numbers of events make rare risks hard to rule out. And 45 of the 56 studies reported that participants were taking mood stabilizers alongside TMS, so the safety data mostly describe people who were already mood-stabilized. In practice, that means TMS for bipolar depression belongs alongside adequate mood stabilization, with a psychiatrist watching for early signs of a switch, such as a reduced need for sleep, racing thoughts, or unusual irritability.

If early signs appear, the psychiatrist can pause sessions and reassess medication before going further. That's one reason TMS for bipolar depression fits best inside ongoing psychiatric care, where the team already knows the person's patterns, rather than as a stand-alone service.

Who Might Be a Candidate

Candidacy is a clinical determination, not a checklist for self-assessment. The profile that fits the research generally includes:

  • A current depressive episode in bipolar I or bipolar II disorder. TMS is used during depression, not during mania or hypomania.
  • Mood stabilization in place, or being started, with a psychiatrist managing it. Our explainer on how mood stabilizers work covers why that foundation matters.
  • Depression that hasn't improved enough with medication and therapy.
  • No contraindications to TMS, such as a history of seizures, metal in the head, or implanted devices like pacemakers.
  • The ability to attend sessions most weekdays for several weeks.

What TMS Does Not Replace

TMS can treat a depressive episode. It does not treat bipolar disorder as a whole.

Mood stabilizers, ongoing psychiatric care, psychotherapy, and steady daily routines remain central to long-term bipolar treatment. TMS doesn't replace any of them, and the need for them continues after the depression lifts. Other options for bipolar depression exist too, including a limited number of medications approved for it and, for severe episodes, electroconvulsive therapy (ECT), which NIMH notes is cleared for severe depressive episodes in bipolar disorder. When the depression lifts, attention turns back to preventing the next episode, through medication, regular follow-up, and a plan for spotting early warning signs. Our overview of effective bipolar disorder treatment covers the broader picture.

Talking to a Psychiatrist About TMS for Bipolar Depression

Whether TMS makes sense for a particular person's bipolar depression is a decision for a psychiatrist who knows the whole history: past manic and hypomanic episodes, how mood stabilizers have worked, what has been tried for depression, and what's safe to add.

At Amae, we specialize in bipolar disorder treatment through a single care team that includes psychiatrists, therapists, primary care, and peer mentors. TMS at our clinics is currently provided for major depressive disorder. If you're living with bipolar depression that hasn't lifted, talk with an Amae psychiatrist about treatment options for bipolar depression. Anyone having thoughts of suicide can call or text 988, at any hour.

Frequently Asked Questions

Is TMS FDA approved for bipolar depression?

No. The FDA has cleared TMS for major depressive disorder, OCD, and a handful of other conditions, but not for bipolar depression. It received a breakthrough device designation for bipolar depression in 2020, which is meant to speed up review but is not clearance, so current use for that condition is off-label.

Can TMS cause a manic episode?

It's possible but uncommon. In the sham-controlled trials pooled in a 2025 meta-analysis, switches into mania or hypomania happened at rates not significantly different from sham treatment: nine cases with active TMS versus four with sham. Most of those studies involved people taking mood stabilizers, the usual setting for TMS in bipolar depression.

How effective is TMS for bipolar depression compared to regular depression?

Comparable, on current evidence. Across 56 studies, about 47% of people with bipolar depression responded and about 28% reached remission, rates the review's authors described as on par with TMS for unipolar depression.

Do I need to be on a mood stabilizer to get TMS for bipolar depression?

Not necessarily as a rule, but it is the usual setting. In the 2025 meta-analysis, 45 of 56 studies reported participants taking mood stabilizers alongside TMS, so most of the safety evidence comes from people who were already mood-stabilized. Whether a mood stabilizer is needed in your case is a decision for your psychiatrist.

Is TMS safe for both bipolar I and bipolar II depression?

The research includes both types, though many participants weren't classified by subtype and results weren't analyzed separately. Safety for any individual depends on their full psychiatric and medical history, which a comprehensive evaluation covers regardless of subtype.

Is TMS for bipolar depression covered by insurance?

Coverage may differ from what plans offer for TMS for major depression. Check with both the provider and your insurance plan before starting.

Citations

1. Judd LL, Akiskal HS, Schettler PJ, et al. The long-term natural history of the weekly symptomatic status of bipolar I disorder. Archives of General Psychiatry. 2002;59(6):530-537. https://pubmed.ncbi.nlm.nih.gov/12044195/ (Tier 1)

2. Ventura F, Frias P, Rodrigues da Silva D, McGirr A, Cotovio G, Oliveira-Maia AJ. Efficacy, effectiveness, and safety of transcranial magnetic stimulation for bipolar depression: a systematic review and meta-analysis. Biological Psychiatry: Global Open Science. 2026 Jan;6(1):100618. Published online 2025 Sep 26. https://pmc.ncbi.nlm.nih.gov/articles/PMC12681701/ (Tier 1)

3. Zhou C, Fabiano N, Wong S, et al. Transcranial magnetic stimulation for bipolar depression: a systematic review and meta-analysis of randomized controlled trials. Canadian Journal of Psychiatry. 2026. https://doi.org/10.1177/07067437261457224 (Tier 1)

4. National Institute of Mental Health. Brain Stimulation Therapies. https://www.nimh.nih.gov/health/topics/brain-stimulation-therapies/brain-stimulation-therapies (Tier 2)

5. 988 Suicide and Crisis Lifeline. https://988lifeline.org (Tier 2)

6. U.S. Food and Drug Administration. Breakthrough Devices Program. https://www.fda.gov/medical-devices/how-study-and-market-your-device/breakthrough-devices-program (Tier 2)